Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight ...

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.

This is the beginning of a revolution, and how you engage and how you attack it is going to really set the stage for your ...

Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.